A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group

Abstract

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) comprises a group of heterogeneous lymphomas that do not fit any other identified PTCL-subgroup and show poor prognosis. To clarify clinical aspects of Japanese PTCL-NOS patients, the Hokkaido Hematology Study Group conducted a multicenter retrospective analysis. The median age of the 107 patients (male 65.4 %) was 67 years. The majority (82.4 %) had stage III/IV disease. Following the international prognostic index, 65.7 % were categorized as high intermediate or high risk. Primary chemotherapy was selected in 96 (90 %) patients, 86 of whom received anthracycline regimens. Sixteen patients received high-dose chemotherapy with autologous stem cell transplantation. Forty-eight (52 %) of the 92 evaluable patients achieved complete remission (CR) or CR/unconfirmed after the primary treatment, in which 22 (46 %) relapsed. The estimated 5-year overall survival (OS) of all patients was 35 %. Three independent risk factors (RFs) associated with OS, bulky disease (hazard ratio HR = 5.324; p = 0.019), age>60 years (HR = 3.015; p = 0.025), and platelet count less than 10 × 10(4)/μL (HR = 3.999; p = 0.036), were identified in a multivariate analysis. Using these three RFs, the OS curves were significantly stratified into three risk groups (low risk, 0 RFs, 3-year-OS 72 %; intermediate risk, one RF, 30 %; high risk, two or three RFs, 0 %; p = 0.0005). These findings may provide valuable information for the management of Japanese PTCL-NOS patients.

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

“…1, 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 In contrast to our study, ∼75% of patients evaluated by the ITCLP were from Europe or Asia. Consequently, AITLs, more prevalent in Europe, and adult T-cell leukemia/lymphomas and natural killer/T cell lymphomas, which are more prevalent in Asia, were all well represented in the ITCLP series, representing ∼39% of the cases examined.…”

“…Therefore, a cutoff of ⩾3 was selected when the IPI was analyzed as a dichotomized variable. 4, 5, 6, 7, 8, 9 All data were analyzed using JMP 8 software (SAS, Cary, NC, USA).…”

Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment

“…This may be partly because the subjects in our study were limited to patients considered able to tolerate CHOP/CHOP-like chemotherapy, and also because our study included some recently diagnosed patients. Furthermore, the CR rate (68%) of CHOP/CHOP-like therapy in our study was relatively higher than that in previous studies (39-53%) [10,[24][25]. This discordance may be also explained by several limitations including the nature of a retrospective analysis, especially various selection biases.…”

Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients

“…In addition, our cohort shared similar clinical and biological characteristics including poor performance status, advanced stage, multiple extranodal involvement, and elevated LDH, which indicated aggressive behavior of the tumors. This could explain the low response rate to conventional chemotherapy like CHOP-based regimen and poor disease outcome of the patients with PTCL (Table 4) [3,4,[17][18][19]. Recent studies showed that peripheral blood parameters turned out to be prognostically relevant in PTCL-NOS.…”